Q. A 60-year-old man with ischemic cardiomyopathy and palpitations is started on amiodarone. Which phase of the cardiac action potential is its primary site of action?

Explanation

## Correct Answer: C. Phase 3 – Repolarization Amiodarone is a **Class III antiarrhythmic** agent whose primary mechanism is **potassium channel blockade**, which prolongs the **action potential duration (APD)** and **refractory period**. Phase 3 (repolarization) is when potassium efflux through voltage-gated K⁺ channels drives the membrane potential back to resting levels. By blocking these K⁺ channels, amiodarone delays repolarization, extending Phase 3 and the effective refractory period (ERP). This increased refractoriness suppresses re-entrant arrhythmias—the primary mechanism of palpitations in ischemic cardiomyopathy. In the clinical scenario of a 60-year-old with ischemic cardiomyopathy and palpitations (likely ventricular arrhythmias or atrial fibrillation), amiodarone's Class III effect on Phase 3 is the therapeutic target. While amiodarone has **additional properties** (Class I, II, and IV effects), its defining and primary antiarrhythmic action is Class III—K⁺ channel blockade during repolarization. This is why it is classified as a Class III agent in the Vaughan-Williams classification used in Indian cardiology practice and KD Tripathi pharmacology. ## Why the other options are wrong **A. Phase 0 – Rapid depolarization** — Phase 0 blockade is the **Class I effect** (sodium channel inhibition), not the primary mechanism of amiodarone. While amiodarone does have weak Class I properties, this is NOT its defining antiarrhythmic action. Class I agents (quinidine, procainamide, flecainide) are used for different arrhythmia substrates. The NBE trap here is confusing amiodarone's secondary Class I effect with its primary Class III mechanism. **B. Phase 4 – Resting potential** — Phase 4 effects relate to **Class II (beta-blockade)** or **Class IV (calcium channel blockade)** mechanisms, which slow automaticity and AV nodal conduction. Amiodarone has these properties secondarily, but they are not its primary antiarrhythmic mechanism. This option tests whether students confuse amiodarone's multiple effects with its defining Class III action. Phase 4 modulation is not the reason amiodarone is chosen for ventricular arrhythmias in cardiomyopathy. **D. Phase 2 – Plateau** — Phase 2 effects relate to **Class IV (calcium channel blockade)**, which shortens the plateau and slows conduction in nodal tissue. Amiodarone has weak Class IV effects but does NOT primarily act on Phase 2. This is a distractor for students who recall amiodarone's multiple properties but fail to identify the **primary** mechanism. The question specifically asks for the primary site of action, not secondary effects. ## High-Yield Facts - **Amiodarone = Class III antiarrhythmic**: primary mechanism is **potassium channel blockade** during Phase 3 repolarization. - **Phase 3 prolongation** increases the **effective refractory period (ERP)**, suppressing re-entrant arrhythmias in ischemic cardiomyopathy. - **Vaughan-Williams classification**: Class I (Na⁺ block, Phase 0), Class II (β-block, Phase 4), Class III (K⁺ block, Phase 3), Class IV (Ca²⁺ block, Phase 2). - Amiodarone has **polypharmacologic properties** (Class I, II, III, IV effects), but Class III (K⁺ blockade) is the **primary and defining** antiarrhythmic action. - **Indian DOC for ventricular arrhythmias** in ischemic cardiomyopathy: amiodarone is preferred over sotalol or dofetilide due to broader spectrum and better hemodynamic profile in acute settings. ## Mnemonics **Class III = K⁺ block = Phase 3** Remember: **III** (Roman numeral 3) = **Phase 3** = **K⁺ channel blockade**. Class III agents prolong repolarization by blocking potassium efflux. Use this when you see 'amiodarone' + 'phase' in a question. **Amiodarone = 'All-in-One' Antiarrhythmic** Amiodarone has **I-II-III-IV** properties, but **Class III is primary**. Think: 'Amiodarone is a Class III agent with extra features,' not the other way around. This prevents confusing its secondary effects with its main mechanism. ## NBE Trap NBE pairs amiodarone with multiple cardiac effects (Class I, II, IV) to lure students into selecting Phase 0, Phase 2, or Phase 4. The trap is confusing amiodarone's **secondary properties** with its **primary defining mechanism**—Class III K⁺ channel blockade during Phase 3. ## Clinical Pearl In Indian cardiology practice, amiodarone is the **first-line antiarrhythmic for hemodynamically unstable ventricular arrhythmias** in ischemic cardiomyopathy because its Class III effect (Phase 3 prolongation) suppresses re-entrant circuits while its Class II effect provides hemodynamic stability—a critical advantage in acute decompensated heart failure settings common in Indian tertiary care. _Reference: KD Tripathi Pharmacology Ch. 31 (Antiarrhythmics); Harrison's Principles of Internal Medicine Ch. 226 (Arrhythmias); Robbins Pathologic Basis of Disease Ch. 11 (Heart)_